Michael Cruse serves as Executive at Reneo Pharmaceuticals, Inc., where they oversee executive responsibilities. Since joining the company, Michael Cruse has executed 8 insider transactions totaling $67.3K, demonstrating a bullish approach to their equity position. Their most recent transaction on Sep 1, 2022 involved purchasing 7,500 shares valued at $25.4K.
Michael Cruse currently holds 13,697 shares of Reneo Pharmaceuticals, Inc. (RPHM), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Michael Cruse has been a net buyer of RPHM stock. They have purchased $67.3K and sold $0 worth of shares.
Michael Cruse's most recent insider trade was on Sep 1, 2022, when they purchased 7,500 shares at $3.39 per share.
Get notified when new Form 4 filings are submitted
| $3.21 |
| Discretionary |
| Aug 30, 2022 | RPHM | $5.9K | Purchase | 1,845 | $3.19 | Discretionary |
| Aug 30, 2022 | RPHM | $3.1K | Purchase | 975 | $3.16 | Discretionary |
| Aug 29, 2022 | RPHM | $3.7K | Purchase | 1,140 | $3.24 | Discretionary |
| Aug 29, 2022 | RPHM | $269 | Purchase | 83 | $3.24 | Discretionary |
| Dec 10, 2021 | RPHM | $0 | Award | 25,000 | $N/A | Discretionary |
| Aug 25, 2021 | RPHM | $18.6K | Purchase | 2,500 | $7.45 | Discretionary |